Fibroblast growth factor 21 for non-alcoholic steatohepatitis

Affiliations

¹ Department of Medicine and Therapeutics 9/F, Clinical Sciences Building, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China. Electronic address: wongv@cuhk.edu.hk.
² University of Western Australia, Perth, WA, Australia.

Comment

Vincent W S Wong et al. Lancet. 2019.

. 2019 Dec 22;392(10165):2658-2660.

doi: 10.1016/S0140-6736(18)32165-2. Epub 2018 Dec 13.

¹ Department of Medicine and Therapeutics 9/F, Clinical Sciences Building, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China. Electronic address: wongv@cuhk.edu.hk.
² University of Western Australia, Perth, WA, Australia.

No abstract available

Comment on

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-DeMarzio D, Kundu S, Noviello S, Luo Y, Christian R. Sanyal A, et al. Lancet. 2019 Dec 22;392(10165):2705-2717. doi: 10.1016/S0140-6736(18)31785-9. Epub 2018 Dec 13. Lancet. 2019. PMID: 30554783 Clinical Trial.